Intervene Immune

What Intervene Immune does

Intervene Immune is a private clinical-stage biotech company headquartered in Torrance, California, developing pharmacological interventions for thymus regeneration to counter age-related immune decline. The company's scientific foundation is the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial, published in Aging Cell in 2019, which was the first clinical study to demonstrate thymus regeneration and a 2.5-year reduction in epigenetic age in human subjects. Its therapeutic approach uses a drug cocktail combining recombinant human growth hormone with DHEA and metformin, and is being extended through the TRIIM-X follow-up trial (NCT04375657, registered 2020). The scientific program is led by Dr. Greg Fahy, a cryobiologist with a track record in thymus biology and anti-aging research, and the company employs 51-100 staff.

Name

Intervene Immune

Legal name

Intervene Immune, Inc.

Website

https://interveneimmune.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Longevity Therapeutics

NAICS

Nursing and Residential Care Facilities (623), Services for the Elderly and Persons with Disabilities (624120)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAAAGAL

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAAGAA

Stem Cell–Based Regenerative Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

• Longevity therapeutics
• Thymus regeneration
• Epigenetic age reversal
• Immune restoration therapy
• Regenerative medicine

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Treatment Programs: Revenue generated from treatment programs for thymus regeneration offered to patients seeking longevity and immune rejuvenation therapies. The company offers clinical treatment programs accessible via their website.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Intervene Immune develops and administers clinical treatment programs that use a proprietary drug cocktail (recombinant human growth hormone combined with DHEA and metformin) to regenerate the thymus gland and reverse age-related immune decline. The company's offering is built around the TRIIM and TRIIM-X clinical protocols — the first studies to demonstrate thymus regeneration and 2.5 years of epigenetic age reversal in humans — and is delivered to patients through direct-enrollment Treatment and Testing Programs at its Torrance, California facility.

Product overview

Intervene Immune is a biotech company pioneering thymus regeneration therapies for human longevity. The company operates as a single-focus therapeutic developer with its core offerings comprising the TRIIM Trial (the first clinical study to demonstrate thymus regeneration and epigenetic age reversal in humans, published 2019) and the TRIIM-X Trial (extended follow-up study), alongside associated Treatment Programs and Testing Programs for patients undergoing thymus regeneration therapy. The company does not operate a multi-product platform but rather develops and delivers its proprietary thymus regeneration approach through clinical trials and treatment programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Thymus Regeneration Treatment Programs

Quantifiable outcome

• 2.5 years of epigenetic age reversal demonstrated in TRIIM trial participants

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Altos Labs: Altos Labs is a well-capitalized longevity biotech pursuing cellular rejuvenation programming. While broader in scope than Intervene Immune, it competes for the same investor mindshare, talent, and patient/consumer interest in human biological age reversal.
• Calico Life Sciences: Calico (an Alphabet-backed longevity company) researches the biology of aging and age-related disease. It overlaps thematically with Intervene Immune's mission to address age-related immune decline, though operating at a much larger and more discovery-focused scale.

Direct peers

• Unity Biotechnology: Unity Biotechnology is a clinical-stage biotech developing therapeutics that clear senescent cells to treat age-related diseases. It is the closest publicly-traded comparable to Intervene Immune: same longevity therapeutic thesis, clinical-stage assets, and small capitalization profile.
• Human Longevity Inc. Human Longevity Inc. is a health intelligence and longevity-focused practice combining diagnostics with preventive interventions for affluent health-conscious consumers. It is a direct comparable on the consumer-facing longevity treatment business model.

Emerging players

• Insilico Medicine: Insilico Medicine uses AI-driven drug discovery to develop therapeutics for age-related disease and longevity. It shares the goal of translating aging biology into clinical-stage therapeutics, making it a comparable emerging player in the longevity pipeline race.
• BioAge Labs: BioAge Labs is a clinical-stage biotech that develops therapeutics targeting the biology of aging using proprietary human aging biology datasets. Its platform-driven approach to identifying age-related drug targets parallels Intervene Immune's mechanism-based immune aging intervention.
• Life Biosciences: Life Biosciences is a longevity biotech developing partial cellular reprogramming and other age-related therapeutics. It is a partial-overlap comparable pursuing different mechanism of action but addressing the same therapeutic area and patient population.
• Rejuvenate Bio: Rejuvenate Bio (a Wyss Institute spinout) develops gene therapy-based treatments for age-related diseases in companion animals and humans. It represents an emerging, mechanism-different approach to the same anti-aging therapeutic opportunity.
• Turn Biotechnologies: Turn Biotechnologies develops epigenetic reprogramming therapies to restore youthful function in aged cells. It targets the same biological age reversal narrative with a different (mRNA-based) technology platform.

Regional players

• TruDiagnostic: TruDiagnostic offers epigenetic age testing and longitudinal biological age monitoring to consumers and clinicians. It complements Intervene Immune's biomarker-based treatment thesis and serves the same consumer segment seeking to track biological aging.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/intervene-immune

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intervene Immune